The claims made in the post by the basher frrol are

New Post Public Reply Private Reply Replies (0) Message Board
Drano
401
The claims made in the post by the basher frrol are deceptive and untrue. Uceris is not the primary drug used for treatment for Ulcerative Colitis. Uceris can have significant side effects. And, claiming the sales figures for Uceris have any relevance to the potential sales for Brilacidin is utterly wrong.

Uceris is a steroid. According to the company's website,
Quote:
UCERIS tablets may reduce the level of flare-ups in the colon, which helps the lining of the colon to heal.

Meanwhile, in a short course of treatment, Brilacidin healed the lesions -- as shown by the gold standard of evidence, photographic proof of before-and-after healing (via sigmoidoscopy). We do not know yet if it is a cure, or merely causes a long-lasting remission -- but it actively heals, and in a shorter course of NON-SYSTEMIC treatment -- Brilacidin 42 days, Uceris 56 days.

Brilacidin has seemingly no significant side effects, as it is not systemically absorbed. What about Uceris? According to the company,
Quote:
UCERIS tablets may weaken your immune system. Taking medicines that weaken your immune system makes you more likely to get infections.
....some people may have too much corticosteroid medicine in their blood (hypercorticism). Talk to your doctor if you have any symptoms of hypercorticism, including: acne, bruising easily, rounding of your face (moon face), ankle swelling, thicker or more hair on your body and face, a fatty pad or hump between your shoulders (buffalo hump), or pink or purple stretch marks on the skin of your abdomen, thighs, breasts, and arms.


It is incredibly deceptive to cherry-pick ONE drug -- Uceris -- out of the vast numbers of drugs used for ulcerative colitis, and then claim that the market for ALL UC drugs is small, because one drug is not used very much.
This is like claiming the market for Bayer-brand aspirin is the entire market for over-the-counter pain relief - - not including Tylenol or any of the NSAIDS like Ibuprofen or Naproxen -- and all of their generics. Contrary to the deceptive post, Uceris is very, very far from being "the go-to drug" for this syndrome.

Drugs used include (broad categories):
Quote:
•5-aminosalicylic acid (5-ASA). Balsalazide, mesalamine, olsalazine, and sulfasalazine are the main medications used to treat ulcerative colitis....
Corticosteroids. [Note: this category includes Uceris as one of many drugs]
•These anti-inflammatory drugs can be used if 5-ASA drugs don't work for you or if you have more severe disease. These medicines sometimes have side effects and long-term complications....
•Immunosuppressants. If corticosteroids or 5-ASA drugs don't help, your doctor may prescribe these kinds of drugs....
•Biologics. This group of drugs includes adalimumab (Humira), adalimumab-atto (Amjevita) and adalimumab-adbm (Cyltezo) - biosimilars to Humira, certolizumab pegol (Cimzia), golimumab (Simponi, SImponi Aria), infliximab (Remicade), ), Infliximab-abda (Renflexis), infliximab-dyyb (Inflectra), a biosimilar to Remicade, tofacitinib (Xeljanz), and vedolizumab (Entyvio).
https://www.webmd.com/ibd-crohns-disease/ulce...-colitis#2



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Indico Breach May Expose Thousands to Identity Theft

Updated Category News Views 1

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

Continue Reading
Palmer's Design Fuels Child Cancer Awareness Drive

Updated Category News Views 6

Imagine a cancer struggle fueling creativity – a hopeful story from the racetrack lights up this reality as Valvoline and a young survivor rev up their engines for children with blood cancer. Powerful Partnership Takes Unforgettable Turn Palmer Goforth, a twelve-year-old cancer survivor, never imagined his hobby of drawing sketches would lead to designing a NASCAR car....

Continue Reading
RELISH 2026: Orange County's Ultimate Food & Drink Bash

Updated Category News Views 0

A Festival Like No Other If there’s anything Orange County knows how to do, it’s throw a party. And here comes RELISH, a three-day feast for the senses that’ll have foodies talking for weeks. Organized by Celebrity Chef Jamie Gwen and Event Planner Nicole Hirsty, this is not your average town fair. This is indulgence on a silver platter, set to take place from...

Continue Reading
Space Collaboration Inches Forward with Extended Talks

Updated Category News Views 1

It seems like every time you blink, the folks over at Maritime Launch Services and Isar Aerospace are at it again. This time, they've decided to extend the deadline for their statement of work by a couple of weeks—now shooting for mid-September 2026. You could say they're taking their time, but really, sometimes that's what you've gotta do when you're trying to launch...

Continue Reading
Salute's T5 Acquisition: A Big Leap in AI/Data Centers

Updated Category News Views 99

Salute's Bold Strategic Acquisition The only constant in the ever-evolving data center industry is change, and Salute has made a significant leap by acquiring T5 Operations. This move fortifies Salute's standing as a leading global service provider for AI, HPC, and cloud infrastructure. By integrating T5's first-rate expertise with their own, Salute isn't just playing the...

Continue Reading
Hormel Foods Gears Up for Barclays Conference

Updated Category News Views 2

Hormel Foods Takes the Stage at Barclays When it comes to branded food, few players can command attention quite like Hormel Foods Corporation. They're set to make a splash at the upcoming 2026 Barclays Global Consumer Staples Conference. On September 9, Jeff Ettinger, interim CEO, and John Ghingo, the CEO-elect, will lead a fireside chat at 1:30 p.m. ET. They're not just...

Continue Reading
Bio-Techne Advances with Science Based Targets in 2026

Updated Category News Views 3

Greenhouse Gas Reduction: A Bright Spot for Bio-Techne Out of the blue, Bio-Techne is turning heads in the sustainability arena. This ain't just another company going through the greenwashing motion; their fiscal 2026 reports underline genuine strides to axe emissions. Celebrated as NASDAQ: TECH to market insiders, Bio-Techne's journey isn't just about profits but carving...

Continue Reading
Teamsters Strike Hits Amazon's Largest U.S. Warehouse

Updated Category News Views 4

Unrest Brewing in Riverside: Amazon's Labor Showdown September 1, 2026, marks a potentially seismic shift in labor disputes within one of America's corporate titans—Amazon. Picture this: workers slinging on their boots, not for a day of hauling goods in Amazon's largest U.S. warehouse, DJT6, but for a united stand outside its gates. Who's at the helm? The Teamsters...

Continue Reading
Adecoagro Expands with Caarapó Mill Acquisition

Updated Category News Views 0

Crushing the Competition: Adecoagro's New Acquisition When there's dirt under your fingernails and deals in the air, taking a strategic swing like Adecoagro just did can be a game-changer. Shelling out R$705 million (roughly US$136 million) in cash isn't what you'd call pocket change, but they're not new to ballsy moves. They've snapped up the Caarapó Mill, previously...

Continue Reading
SCO Agenda: Development, Security, and Global Equity

Updated Category News Views 3

China's Vision for a Balanced World In a world chock-full of friction and uncertainty, President Xi's proclamation at the recent SCO meeting has struck a chord. The SCO, once a fledgling idea among nations, now stands on the global stage with Xi's ringing call for it to prioritize development and equity in governance. A Subtle Shift in the Global South's Influence Xi's...

Continue Reading

Top 5 Most Recently Viewed Articles

Stifel Affirms Buy Rating for STAAR Surgical Amid Market Challenges

Updated Category News Views 64

Stifel Affirms Strong Support for STAAR Surgical Recently, Stifel renewed its Buy rating for STAAR Surgical (NASDAQ:STAA), setting a target price of $44.00 per share. This upbeat assessment comes even amid broader market challenges. By analyzing various data points from China's refractive sector, Stifel suggests that the second half of 2024 could show signs of recovery...

Continue Reading
Ryan Detert's Million-Dollar Gift Transforms Youth Mentorship

Updated Category News Views 311

Ryan Detert's Generous Donation to Change Young Lives Ryan Detert, CEO of Influential, has made a significant commitment to fostering mentorship within the fabric of America’s youth. The extraordinary decision to donate $1 million is not just a charitable act; it symbolizes a passionate dedication to the mission of Big Brothers Big Sisters of America. This initiative,...

Continue Reading
Alvotech's AVT03 Secures EMA Positive Opinion for Approval

Updated Category News Views 183

Positive EMA Opinion for Alvotech's AVT03 Alvotech (NASDAQ: ALVO), a prominent biotech firm known for its innovative biosimilar medicines, has recently made headlines with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) endorsing its investigational product AVT03. This biosimilar is proposed as a counterpart to Prolia...

Continue Reading
Exploring the Future of Shared Mobility: Trends and Innovations

Updated Category News Views 215

The Momentum of Shared Mobility Market Growth The shared mobility market is undergoing rapid transformation fueled by urbanization and the increasing demand for sustainable transportation solutions. A growing population in urban areas leads to increased traffic congestion and parking limitations, pushing consumers towards shared mobility options. These services offer...

Continue Reading
Exploring Global Innovation at CIFTIS 2025 Exhibition

Updated Category News Views 196

Global Engagement at CIFTIS 2025 The much-anticipated 2025 China International Fair for Trade in Services (CIFTIS) has opened its doors, showcasing a significant gathering of 85 nations and various international organizations. This event is not just a fair; it represents a collective vision for trade, emphasizing cooperation and innovation among diverse cultures....

Continue Reading